Proteros Enters into a Research Agreement for Structure Based Lead Generation
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Proteros biostructures GmbH (Proteros) announced that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), under which Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD.
Under the agreement, Proteros will deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Torsten Neuefeind, Chief Executive Officer for Proteros, stated that “this partnership will build on a long standing and successful relationship.”
Under the agreement, Proteros will deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.
Torsten Neuefeind, Chief Executive Officer for Proteros, stated that “this partnership will build on a long standing and successful relationship.”
